Elizabeth Spencer
Appearances
- DateMay 7, 2023BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
Speakers
Icahn School of Medicine, Mount SinaiPresenter
Icahn School of Medicine at Mount Sinai Department of Pediatrics - DateMay 8, 2023BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
Presenter
Icahn School of Medicine at Mount Sinai Department of PediatricsSpeakers
Icahn School of Medicine, Mount Sinai - DateMay 18, 2024INTRODUCTION: Stride-II recommends early biomarker targets for treatment optimization to achieve treat-to-target (T2T) endoscopic remission (ER) in ulcerative colitis (UC). Predictive capabilities of intestinal ultrasound (IUS) for T2T ER remains unknown…
Presenter
Icahn School of Medicine at Mount Sinai Department of PediatricsSpeakers
